Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large numb...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Biomed Res Int
Egile Nagusiak: Signorelli, Diego, Giannatempo, Patrizia, Grazia, Giulia, Aiello, Marco Maria, Bertolini, Federica, Mirabile, Aurora, Buti, Sebastiano, Vasile, Enrico, Scotti, Vieri, Pisapia, Pasquale, Cona, Maria Silvia, Rolfo, Christian, Malapelle, Umberto, Group, Immune-Oncology YOUNG
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2019
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507101/
https://ncbi.nlm.nih.gov/pubmed/31179334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/9056417
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak